Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Madrid
Clinical trial register · Spain

Clinical Trials in Madrid, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 80 Madrid 65 Seville 37 Valencia 34 Málaga 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca183 Janssen Research & Development, LLC109 Merck Sharp & Dohme LLC106 Novartis Pharmaceuticals100 Hoffmann-La Roche92 Clear sponsor filter
Site location
Barcelona80 Madrid65 Seville37 Valencia34 Málaga18
All 78 locations
Target enrolment
to

Trials with a site in Madrid

65 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Eli Lilly and Company
Phase 3
150
Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz
2026-09
Recruiting
Eli Lilly and Company
Phase 3
2,001
Alcobendas, Barcelona, Centelles, Ferrol, Granada, Madrid, Pozuelo de Alarcón, Seville
2026-08-26
Recruiting
Eli Lilly and Company
Phase 3
1,000
Barcelona, Centelles, Madrid, Oviedo, Salamanca, Seville, Zamora
2026-08-14
Recruiting
Eli Lilly and Company
Phase 3
252
A Coruña, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Seville, Valencia
2026-06-01
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Barcelona, Madrid
2026-05-28
Recruiting
Eli Lilly and Company
Phase 2
531
Barcelona, Centelles, Granada, Madrid, Marbella, Salamanca, Santiago de Compostela
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
342
Barcelona, Centelles, Granada, Madrid, Marbella, Salamanca, Santiago de Compostela
2026-04-29
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Barcelona, Madrid
2026-04-17
Recruiting
Eli Lilly and Company
Phase 3
800
Guadalajara, Lleida, Logroño, Madrid, Málaga, Seville
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Barcelona, Madrid, Oviedo, Salamanca, Zamora
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
300
Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Santander, Seville, Valencia
2026-02-05
Recruiting
Eli Lilly and Company
Phase 3
150
Barakaldo, Esplugues de Llobregat, Madrid
2026-01-12
Recruiting
Eli Lilly and Company
Phase 3
1,035
Alzira, Barcelona, Madrid, Málaga, Santiago de Compostela, Seville
2025-12-15
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Barcelona, Madrid, Mataró, Málaga, Reus
2025-11-28
Recruiting
Eli Lilly and Company
Phase 2
252
Barcelona, Fuenlabrada, Gijón, Madrid
2025-11-10
Recruiting
Eli Lilly and Company
Phase 3
1,630
Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
4,500
A Coruña, Badalona, Barcelona, Ferrol, Huelva, Madrid, Palma, Pontevedra
2025-10-15
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Barcelona, Madrid
2025-08-06
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
Barcelona, Madrid
2025-07-28
Recruiting
Eli Lilly and Company
Phase 3
290
Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
350
Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia
2025-06-26
Active, closed
Eli Lilly and Company
Phase 3
465
Badajoz, Badalona, Barcelona, Madrid, Seville
2025-05-12
Recruiting
Eli Lilly and Company
Phase 3
700
Badajoz, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, Madrid, Málaga, Palma
2025-03-27
Recruiting
Eli Lilly and Company
Phase 3
125
Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz
2024-11-18
Active, closed
Eli Lilly and Company
Phase 2
45
Barcelona, Córdoba, Esplugues de Llobregat, Madrid, Seville, Valencia
2024-10-25
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab
Eli Lilly and Company
Phase 1
750
Barcelona, Madrid, Málaga
2024-10-21
Active, closed
Eli Lilly and Company
Phase 2
143
Barcelona, Ciudad Real, Córdoba, Huelva, Las Palmas de GC, Madrid, Santiago de Compostela, Seville
2024-10-10
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
Barcelona, Madrid
2024-09-19
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Barcelona, Madrid
2024-09-12
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
Barcelona, Madrid, Seville
2024-07-01
Recruiting
Eli Lilly and Company
Phase 3
300
Barcelona, Córdoba, Madrid, Málaga, Valencia
2024-06-03
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin
Eli Lilly and Company
Phase 1
575
Barcelona, Madrid, Valencia
2024-05-20
Recruiting
Eli Lilly and Company
Phase 3
510
Andalucia, Barcelona, Cadiz, Galícia, Madrid, Pamplona
2024-04-29
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Barcelona, Madrid, Seville
2024-03-05
Recruiting
Eli Lilly and Company
Phase 1/2
880
Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Reus, Seville
2023-04-17
By invitation
Eli Lilly and Company
Phase 3
333
Esplugues de Llobregat, Las, Madrid, Pozuelo de Alarcón, Pamplona, Pontevedra, Manises
2023-03-09
Recruiting
Eli Lilly and Company
Phase 3
595
Badalona, Barcelona, Bilbao (Bizkaia), Madrid, Valencia
2023-02-27
Recruiting
Eli Lilly and Company
Phase 1
677
Barcelona, Madrid, Santander
2023-01-12
Active, closed
Eli Lilly and Company
Phase 3
377
Esplugues de Llobregat, Las, Madrid, Pamplona
2022-10-18
Active, closed
Eli Lilly and Company
Phase 2
46
Barcelona, Esplugues de Llobregat, Madrid, Seville, Valencia
2022-09-20
Recruiting
Eli Lilly and Company
Phase 1
260
Barcelona, Madrid, Pozuelo de Alarcón, Valencia
2022-05-11
Active, closed
Eli Lilly and Company
Phase 3
925
Hospitalet, Madrid, Valencia, Badajoz, Seville
2022-04-14
Active, closed
Eli Lilly and Company
Phase 3
874
Barcelona, Cáceres, Lleida, Madrid, San Cristóbal de La Laguna, Valencia, Granada, Seville
2021-10-04
Active, closed
Eli Lilly and Company
Phase 3
101
Esplugues de Llobregat, Madrid, Málaga, Seville, Valencia
2021-04-13
Active, closed
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
DrugsLY3410738·Azacitidine·Venetoclax
Eli Lilly and Company
Phase 1
260
Barcelona, Madrid, Valencia
2020-11-19
Active, closed
Eli Lilly and Company
Phase 1
200
Barcelona, Madrid
2020-10-01
Active, closed
Eli Lilly and Company
Phase 1
71
Barcelona, Madrid
2020-06-11
Active, closed
Eli Lilly and Company
Phase 3
58
Esplugues de Llobregat, Madrid, Seville, Valencia
2020-02-12
Recruiting
Eli Lilly and Company
Phase 2
105
Barcelona, Esplugues de Llobregat, Madrid, San Cristóbal de La Laguna, Seville, Valencia
2020-01-22
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Barcelona, Madrid, Valencia
2019-12-10
Active, closed
Eli Lilly and Company
Phase 3
30
Esplugues de Llobregat, Madrid, Valencia
2019-10-16
Recruiting
Eli Lilly and Company
Phase 3
190
Esplugues de Llobregat, Madrid, Seville, Valencia
2019-04-05
Active, closed
Eli Lilly and Company
Phase 2/3
393
Barcelona, Hospitalet, Madrid, Málaga
2018-11-26
Active, closed
Eli Lilly and Company
Phase 3
1,058
Alicante, Fuenlabrada, Girona, Huelva, Las Palmas de GC, Madrid, Oviedo, Sagunto
2018-07-18
Active, closed
Eli Lilly and Company
Phase 3
5,637
Córdoba, Barcelona, Santiago de Compostela, Lleida, Pozuelo de Alarcón, Alcorcón, Madrid, Málaga
2017-07-12
Active, closed
Eli Lilly and Company
Phase 1/2
857
Barcelona, Madrid
2017-05-02
Active, closed
Eli Lilly and Company
Phase 1
223
Barcelona, Madrid, Valencia
2016-11-21
Active, closed
Eli Lilly and Company
Phase 1
100
Ávila, Cáceres, Madrid
2016-11-14
Active, closed
Eli Lilly and Company
Phase 2
234
Barcelona, Madrid, Valencia
2016-09-14
Active, closed
Eli Lilly and Company
Phase 2
309
L'Hospitalet de Llobregat, Barcelona, Madrid
2016-05-19
Active, closed
Eli Lilly and Company
Phase 3
545
Barcelona, Hospitalet, Palma, Pozuelo de Alarcón, Madrid, Pamplona, Seville, Valencia
2015-05-06
Active, closed
Eli Lilly and Company
Phase 3
493
Badajoz, Barcelona, Donostia / San Sebastian, Lleida, Madrid, Valencia
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
453
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Valencia
2014-10-03
Active, closed
Eli Lilly and Company
Phase 3
669
Elche, Barcelona, Lleida, Madrid, Murcia, Valencia
2014-07-22
Active, closed
Eli Lilly and Company
Phase 2
110
Barcelona, Madrid
2012-05-22
Rows per page Showing 1–65 of 65
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/madrid

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 65 of those studies with a site in Madrid that also match the filters currently applied.

How many clinical trials are recruiting in Madrid?

34 of the 65 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 29 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Madrid), 65 studies
PhaseStudiesRecruitingShare
Phase 3331850.8%
Phase 1181027.7%
Phase 211516.9%
Phase 1/2213.1%
Phase 2/3101.5%

Most active sponsors

Lead sponsors with the most studies (Madrid)
Lead sponsorStudiesRecruiting
Eli Lilly and Company6534
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.